Lumos Diagnostics is a Carlsbad-based point-of-care diagnostic company on Loker Avenue West developing and manufacturing rapid lateral-flow immunoassays for infectious disease differentiation. The FDA 510(k)-cleared FebriDx test (K230917) detects Myxovirus resistance protein A and C-reactive protein simultaneously from a fingerstick blood sample, distinguishing bacterial from viral infection within minutes — the kind of rapid triage tool deployed at walk-in clinics such as Perlman Clinic Carlsbad Village. Originally spun off from Australia-based Planet Innovation and merged with RPS Diagnostics, the combined entity now operates from the 92010 ZIP code's Poinsettia industrial district under ASX ticker LDX. Custom assay development, disposable reader engineering, cloud-based data connectivity, and contract manufacturing services extend the platform beyond proprietary products to third-party diagnostic partners. Antimicrobial stewardship is the clinical rationale behind FebriDx: reducing unnecessary antibiotic prescriptions by confirming viral etiology at the point of care, a screening philosophy shared with the evidence-based diagnostic protocols at San Diego Ear, Nose & Throat Specialists for upper respiratory presentations. Colorimetric and fluorescent label options on the disposable reader platform support both qualitative and quantitative assay configurations with Bluetooth output to smartphone or tablet interfaces.